Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mut...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Commun
Main Authors: Van Emburgh, Beth O., Arena, Sabrina, Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Corti, Giorgio, Mussolin, Benedetta, Baldi, Federica, Buscarino, Michela, Bartolini, Alice, Valtorta, Emanuele, Vidal, Joana, Bellosillo, Beatriz, Germano, Giovanni, Pietrantonio, Filippo, Ponzetti, Agostino, Albanell, Joan, Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Montagut, Clara, Bardelli, Alberto
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5155160/
https://ncbi.nlm.nih.gov/pubmed/27929064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13665
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki